Evaluation of microparticle enzyme immunoassay against HPLC-mass spectrometry for the determination of whole-blood tacrolimus in heart- and lung-transplant recipients

Clinical Biochemistry

Volumn 33, Issue 7, 2000, Pages 557-562

  Salm, Paul ^a   Rutherford, David M ^c   Taylor, Paul J ^a,b   Black, Marion J ^c   Pillans, Peter I ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c Alfred Pathology Service   (Australia)

Author keywords

HPLC MS; Microparticle enzyme immunoassay; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

ASCOMYCIN; TACROLIMUS;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG TRANSPLANTATION; MALE; MASS SPECTROMETRY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 0034537458     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(00)00163-6     Document Type: Article

References (25)

1. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results
2. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation
3. A prospectire randomized trial of FK506 versus cyclosporin after human pulmonary transplantation
4. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation
5. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation
6. Clinical pharmacokinetics of tacrolimus
7. Clinical pharmacokinetics of tacrolimus in heart transplant recipients
8. Consensus document: Therapeutic monitoring of tacrolimus (FK-506)
9. Tacrolimus metabolite cross-reactivity in different tacrolimus assays
10. Pitfalls in monitoring tacrolimus (FK506)
11. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry
12. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry
13. Statistical methods for assessing agreement between two methods of clinical measurement
14. Therapeutic drug monitoring of cyclosporin and tacrolimus
15. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
16. Analytical goals in therapeutic drug monitoring
17. Analytical requirements for immunosuppressive drugs in clinical trials
18. Evaluation of the tacrolimus II enzyme immunoassay (MEIA II) in liver and renal transplant recipients
19. Therapeutic monitoring of tacrolimus (FK506) with the first and second generation microparticle enzyme immunoassays: Performance and results in four patient populations
20. Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassay in liver and kidney transplantation
21. IMx tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients
22. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: Comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA II)
23. Isolation, identification and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone